KORU Medical Q4 revenue rises 23%

Koru Medical Systems

12/03/2026 21:10

Overview

U.S. infusion device maker's Q4 revenue rose 23% yr/yr, full year up 22%

Company posted positive adjusted EBITDA for Q4 and full year

2026 guidance calls for 15-22% revenue growth, positive adjusted EBITDA and cash flow

Outlook

KORU Medical expects 2026 net revenues between $47.5 mln and $50.0 mln, up 15-22%

Company sees 2026 gross margin between 61% and 63%

Company expects positive adjusted EBITDA and positive cash flow for full year 2026

Result Drivers

SCIg DEMAND - Co said domestic core revenue growth was driven by SCIg market growth and new patient starts

INTERNATIONAL EXPANSION - International core revenue growth was driven by increased penetration in established markets and new geographic entries

MATERIAL COSTS AND TARIFFS - Gross margin declined mainly due to higher material costs and tariffs, partially offset by higher average selling prices

Company press release: ID:nBw7bfk1Ba

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$500,000
Q4 Gross Margin
62.6%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for KORU Medical Systems Inc is $7.00, about 55.2% above its March 11 closing price of $4.51

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)